Targets › ABCC9
4 programs from 4 companies in 7 trials: 2 Phase 3, 2 Phase 4, 2 Phase 2, 1 Phase 1; Immunology, Oncology, Neurology; next expected readout Nov 2026.
Subunit of ATP-sensitive potassium channels (KATP). Can form cardiac and smooth muscle-type KATP channels with KCNJ11. (UniProt, O60706)
Open in Phaseline: the race on ABCC9, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Korea University Anam Hospital | Nicorandil ATP-sensitive potassium channel opener with nitrate-like properties | ABCC9 | Phase 4 | No-Reflow Phenomenon | May 2027 |
| Industrial Farmacéutica Cantabria | Minoxidil Sulfonylurea receptor 2, Kir6.2 opener | Ion channels, ABCC9 | Phase 3 | Androgenetic Alopecia; Central Centrifugal Cicatricial Alopecia (CCCA); Survivors of Childhood Cancer; Breast Reconstruction | Nov 2026 |
| Zhejiang Sunshine Mandi Pharmaceutical | Minoxidil Sulfonylurea receptor 2, Kir6.2 opener | Ion channels, ABCC9 | Phase 3 | Androgenetic Alopecia | Dec 2027 |
| Gregory Jicha, MD, PhD | Nicorandil ABCC9 (ATP-sensitive potassium channel) modulator | ABCC9 | Phase 2 | Dementia | Nov 2026 |
Androgenetic Alopecia (2) Central Centrifugal Cicatricial Alopecia (CCCA) (1) Survivors of Childhood Cancer (1) Breast Reconstruction (1) Dementia (1) No-Reflow Phenomenon (1)
small molecule (4)
Industrial Farmacéutica Cantabria (1) Gregory Jicha, MD, PhD (1) Zhejiang Sunshine Mandi Pharmaceutical (1) Korea University Anam Hospital (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.